Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention,...

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering superior survival rates and patient tolerance over traditional chemotherapy.
• Significant knowledge gaps persist regarding ICI toxicity profiles, their correlation with treatment efficacy, and the reasons behind variable patient responses.
• The search for predictive biomarkers for ICI response and toxicity is ongoing, aiming to optimize treatment and mitigate severe adverse events.

Purpose of the Study:

• To investigate the complex relationship between immune checkpoint inhibitor (ICI) toxicity and treatment response in oncology.
• To analyze the molecular underpinnings of differential patient responses to ICIs, distinguishing responders from non-responders.
• To address the critical question of whether predictive biomarkers for severe immune-related adverse events are necessary or if early toxicity management is preferable to preserve anti-tumor immunity.

Main Methods:

• Comprehensive literature review and in-depth analysis of existing research on immune checkpoint inhibitors (ICIs).
• Examination of molecular mechanisms associated with ICI efficacy and immune-related adverse events (irAEs).
• Exploration of the interplay between toxicity, treatment response, and long-term survivorship in patients receiving immunotherapy.

Main Results:

• Some studies indicate a potential correlation between severe adverse events and enhanced long-term survival in patients treated with ICIs.
• The necessity of biomarkers to predict severe immune-related adverse events (irAEs) prior to their onset is debated.
• Concerns exist that early intervention for toxicity might compromise the sustained anti-tumor immune response crucial for durable efficacy.

Conclusions:

• Understanding the molecular basis of ICI response and toxicity is crucial for optimizing cancer immunotherapy.
• The potential benefit of severe adverse events on long-term survival warrants further investigation.
• Balancing the management of irAEs with the preservation of anti-tumor immunity remains a key challenge in ICI therapy.